Nexletol receives regulatory approval in Japan
Hypercholesterolaemia treatment Nexletol has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare.
The announcement was made by US pharmaceutical company Esperion, whose partner Otsuka Pharmaceutical has developed and commercialised Nexletol. The product is a treatment for hypercholesterolaemia and familial hypercholesterolaemia.
“Securing regulatory approval in Japan – one of the top three global markets for cardiovascular prevention – represents a major step forward in our international growth strategy,” said Sheldon Koenig, President and CEO of Esperion. “With Nexletol now approved across the US, Europe and Japan, we’ve established a strong global footprint and expanded access to a differentiated, non-statin LDL-C lowering therapy for patients who need alternatives.”
“Our partnership with Otsuka positions us to unlock significant value in Japan, and we remain focused on driving long-term growth and shareholder value through continued innovation and market expansion.”
Under the terms of the collaboration and license agreement, Esperion is eligible to receive significant milestone payments upon regulatory approval and National Health Insurance Price Listing for Nexletol in the Otsuka territory. Esperion is also eligible to receive additional sales milestone payments based on total net sales achievements by Otsuka in Japan, as well as tiered royalties ranging from 15% to 30% on net sales in Japan.
Bruno Quinney, Content Team, DDW
